首页> 外文期刊>Bone marrow transplantation >Secondary oral cancer following hematopoietic cell transplantation.
【24h】

Secondary oral cancer following hematopoietic cell transplantation.

机译:次生细胞移植后次生口腔癌。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this retrospective study was to determine the incidence and the clinical outcome of secondary oral cancer (SOC) and to assess potential risk factors in a large cohort of patients (n?=?908), who received allogeneic hemopoietic cell transplantation (HCT) either for a malignant (n?=?733) or nonmalignant hematologic disease (n?=?175). The median follow-up of 438 transplant survivors was 17 years. Twelve patients developed SOC at a median of 13.5 years since HCT and at a median age of 47 years. The 35-year cumulative incidence function of SOC development was 3.47%. In univariate analysis, factors associated with increased incidence of SOC were reduced intensity conditioning and chronic graft-versus-host disease (cGvHD). On multivariate analysis, nonmalignant disease and duration of oral cGvHD ≥15 months were independent risk factors for SOC development. Nonmalignant disease recipients had 3.94× higher than expected rate of SOC (95% confidence interval, 1.50-10.39%, p?=?0.0055). Recipients whose oral cGvHD persisted for more than ≥15 months had 58.6× higher than expected rate of SOC (95% confidence interval, 13.3-258.1%), p?
机译:该回顾性研究的目的是确定次生口腔癌(SOC)的发病率和临床结果,并评估接受同种异体杂种细胞移植(HCT )对于恶性(n?=α733)或非恶性血液疾病(n?=α175)。 438移植幸存者的中位随访是17年。十二名患者在HCT中位于13.5岁以上的中位数,在47岁的中位。 SoC发展的35年累计发作率为3.47%。在单变量分析中,与SoC发病率增加相关的因素降低了强度调节和慢性接枝与宿主疾病(CGVHD)。在多变量分析中,非血管疾病和口服CGVHD≥15个月的持续时间是SoC发展的独立危险因素。非空血症疾病受者的SOC预期率高3.94倍(95%置信区间,1.50-10.39%,p?= 0.0055)。口服CGVHD持续超过≥15个月的接收者具有58.6倍的SoC预期率(95%置信区间,13.3-258.1%),p?<0.0001)。本研究表明,口腔CGVHD和非开始性血液疾病的诊断是SoC发展中的强烈危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号